You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

CLINICAL TRIALS PROFILE FOR CARBOCAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Carbocaine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01981291 ↗ Duration of Sciatic Nerve Block After Injection of Local Anesthetic In or Around the Nerve Completed University of Parma Phase 4 2012-10-01 This study was designed to assess whether the injection of local anesthetic into the nerve (intraneural), as opposed to around it (perineural), leads to longer anesthesia and analgesia of the leg. Some reports of accidental intraneural injection mention an extremely long duration. When different drugs and doses were evaluated in a clinical trial of intraneural injection, a longer-than-expected duration was reported. The investigators will compare the two types of injection using the same drug, so as to determine if there is an actual difference in duration.
NCT02384915 ↗ Spinal Anesthesia Versus Combined Sciatic-femoral Nerve Block for Outpatient Knee Arthroscopy Completed ASST Gaetano Pini-CTO Phase 4 2015-01-01 The aim of the study is to compare the time of home discharge in day-case patients receiving either a spinal anesthesia or a combined sciatic-femoral nerve block for knee arthroscopy
NCT02829697 ↗ The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability Completed Innovation Fund Denmark Phase 4 2016-07-01 The aim is to investigate the effect of perineural administration of a series of different volumes of local anaesthesia (ropivacaine 0.2%) on nerve block duration and the variability of the duration in the common peroneal nerve and the sciatic nerve in healthy volunteers. The hypothesis is that nerve block duration is correlated to local anaesthetic volume, but only to a certain degree. After a sufficient volume a 'saturation level' will be reached, and nerve block duration will not increase further.
NCT02829697 ↗ The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability Completed Nordsjaellands Hospital Phase 4 2016-07-01 The aim is to investigate the effect of perineural administration of a series of different volumes of local anaesthesia (ropivacaine 0.2%) on nerve block duration and the variability of the duration in the common peroneal nerve and the sciatic nerve in healthy volunteers. The hypothesis is that nerve block duration is correlated to local anaesthetic volume, but only to a certain degree. After a sufficient volume a 'saturation level' will be reached, and nerve block duration will not increase further.
NCT03390426 ↗ Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension Completed Duke University Phase 4 2018-05-03 The purpose of this prospective randomized double-blind study is to determine if the novel technique of ultrasound guided peri-arterial injection of local anesthetic around the femoral artery decreases ischemic hypertension associated with prolonged lower extremity tourniquet time during total ankle arthroplasty (TAA) and foot fusion surgeries. Patients will be randomized 1:1 to receive either local anesthetic or saline, which will be injected superomedially to the femoral artery in an attempt to block sympathetic afferents and decrease tourniquet associated hypertension intraoperatively.
NCT04454203 ↗ Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension Recruiting Duke University Phase 4 2021-02-05 The goal of this prospective randomized double-blind study is to determine if an ultrasound guided peri-arterial injection of local anesthetic (LA) superomedially the femoral artery via peripheral nerve catheter reverses ischemic hypertension associated with prolonged lower extremity tourniquet time.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Carbocaine

Condition Name

Condition Name for Carbocaine
Intervention Trials
Ankle Fusion 2
Intraoperative Hypertension 2
Postoperative Pain 2
Total Ankle Arthroplasty 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Carbocaine
Intervention Trials
Pain, Postoperative 2
Hypertension 2
Arthritis 1
Pulpitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Carbocaine

Trials by Country

Trials by Country for Carbocaine
Location Trials
United States 3
Italy 2
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Carbocaine
Location Trials
North Carolina 2
Indiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Carbocaine

Clinical Trial Phase

Clinical Trial Phase for Carbocaine
Clinical Trial Phase Trials
Phase 4 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Carbocaine
Clinical Trial Phase Trials
Completed 4
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Carbocaine

Sponsor Name

Sponsor Name for Carbocaine
Sponsor Trials
Duke University 2
University of Parma 1
ASST Gaetano Pini-CTO 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Carbocaine
Sponsor Trials
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

CARBOCAINE: Clinical Trials, Market Analysis, and Projections

Introduction to CARBOCAINE

CARBOCAINE, also known as mepivacaine hydrochloride, is an amide-type local anesthetic used for the production of local or regional analgesia and anesthesia. It is administered through various methods, including local infiltration, peripheral nerve block techniques, and central neural techniques such as epidural and caudal blocks[2][3].

Clinical Trials Update

Current Studies and Findings

One of the recent and notable clinical trials involving CARBOCAINE is focused on its effects on neurological sequelae of cerebral infarction. In this Phase 2 study, patients suffering from chronic neurological symptoms of stroke were treated with subcutaneous injections of mepivacaine.

  • Key Findings: A patient with cortical blindness after a bi-occipital infarction showed significant improvement in vision following the administration of mepivacaine. This improvement was maintained for several days and repeated with each injection. The study suggests functional changes in the peri-lesional areas on resting-state functional MRI, indicating potential therapeutic benefits of mepivacaine in certain neurological conditions[4].

Implications and Future Directions

This study opens up new avenues for the use of CARBOCAINE in neurology, particularly in the management of stroke-related neurological deficits. Further research is needed to fully understand the mechanisms and to establish the safety and efficacy of mepivacaine in these contexts.

Dosage and Administration

Important Considerations

  • Test Dose: Before administering the full dose of CARBOCAINE, especially in caudal and lumbar epidural blocks, a test dose with epinephrine is recommended. This test dose should contain 10-15 mcg of epinephrine and 45-50 mg of CARBOCAINE to detect unintended intravascular or intrathecal injection[1][2].
  • Dosage Limits: The recommended single adult dosage should not exceed 400 mg, and the total daily dosage should not exceed 1,000 mg in 24 hours. Repeat administration should not occur at intervals of less than 1.5 hours[2].
  • Special Populations: Elderly patients and those with hepatic or renal impairment require reduced dosages and increased monitoring due to the slow accumulation and metabolic degradation of the anesthetic[1][3].

Market Analysis

Global Local Anesthesia Drugs Market

The global local anesthesia drugs market is projected to grow at a CAGR of 3.6% from 2024 to 2030, with the market size valued at USD 4.01 billion in 2023[5].

  • Market Share: While lidocaine dominates the market with a 28.7% share, other local anesthetics like ropivacaine are expected to register significant growth due to their favorable safety profiles and longer durations of action[5].
  • Segmentation: The market is segmented by drug type, application, and region. Injectable anesthetics, which include CARBOCAINE, are a major segment within the market[5].

Competitive Landscape

CARBOCAINE, along with other local anesthetics, faces competition from a range of products. However, its specific indications and use cases, particularly in epidural and caudal blocks, maintain its relevance in the market.

  • Regional Outlook: The market is geographically diverse, with North America, Europe, and the Asia Pacific being key regions. The growth in these regions is driven by increasing demand for pain management solutions and advancements in medical procedures[5].

Projections and Future Outlook

Market Growth Drivers

  • Increasing Demand for Pain Management: The growing need for effective pain management strategies, especially in post-operative care and chronic pain management, is expected to drive the demand for local anesthetics like CARBOCAINE.
  • Advancements in Medical Procedures: The development of new medical procedures and the expansion of existing ones will continue to support the growth of the local anesthesia market[5].

Challenges and Opportunities

  • Safety and Efficacy: Ensuring the safety and efficacy of CARBOCAINE, particularly in new clinical applications, will be crucial for its continued market presence.
  • Regulatory Environment: Compliance with regulatory requirements and ongoing clinical trials will be essential for maintaining and expanding the market share of CARBOCAINE[2][3].

Key Takeaways

  • Clinical Trials: CARBOCAINE is being explored for its potential in treating neurological sequelae of cerebral infarction, showing promising results.
  • Dosage and Administration: Strict adherence to dosage guidelines and the use of test doses are critical for safe administration.
  • Market Analysis: The global local anesthesia market is growing, with CARBOCAINE maintaining its position due to its specific use cases.
  • Future Outlook: The market is expected to grow driven by increasing demand for pain management and advancements in medical procedures.

FAQs

What is CARBOCAINE used for?

CARBOCAINE is used for the production of local or regional analgesia and anesthesia through methods such as local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks[2][3].

What are the key considerations for administering CARBOCAINE?

Key considerations include the use of a test dose with epinephrine to detect unintended intravascular or intrathecal injection, and adherence to dosage limits to avoid toxicity[1][2].

Is CARBOCAINE safe for patients with hepatic or renal impairment?

Patients with hepatic or renal impairment require reduced dosages and increased monitoring due to the slow accumulation and metabolic degradation of the anesthetic[1][3].

What is the current market size and growth projection for local anesthesia drugs?

The global local anesthesia drugs market was valued at USD 4.01 billion in 2023 and is projected to grow at a CAGR of 3.6% from 2024 to 2030[5].

Are there any ongoing clinical trials for new uses of CARBOCAINE?

Yes, there are ongoing clinical trials exploring the use of CARBOCAINE in treating neurological sequelae of cerebral infarction, showing promising results[4].

How does CARBOCAINE compare to other local anesthetics in the market?

CARBOCAINE has specific indications and use cases, particularly in epidural and caudal blocks, which maintain its relevance in the market despite competition from other local anesthetics like lidocaine and ropivacaine[5].

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.